Deregulation of microRNA expression in thyroid tumors

MicroRNAs (miRNAs or miRs) are endogenous non-coding RNAs that negatively regulate gene expression by binding to the 3′ non-coding regions of target mRNAs, resulting in their cleavage or blocking their translation. miRNAs may have an impact on cell differentiation, proliferation, and survival, and their deregulation can be inclined to diseases and cancers, including thyroid tumors. The purpose of this review is to summarize the existing findings of deregulated miRNAs in different types of thyroid tumors and to exhibit their potential target genes, especially to demonstrate those involved in tumor invasion and metastasis. In addition, new findings of circulating miRNA expression profiles, single nucleotide polymorphism (SNP) in thyroid tumors, and the correlation of somatic mutations with deregulated miRNA expression in thyroid tumors were all included in this review.

[1]  Qingwei Wang,et al.  The association of miR-146a rs2910164 and miR-196a2 rs11614913 polymorphisms with cancer risk: a meta-analysis of 32 studies. , 2012, Mutagenesis.

[2]  A. Pinchera,et al.  MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration. , 2012, European journal of endocrinology.

[3]  M. Rugge,et al.  MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. , 2012, Thyroid : official journal of the American Thyroid Association.

[4]  H. Mazeh.  MicroRNA as a diagnostic tool in fine-needle aspiration biopsy of thyroid nodules. , 2012, The oncologist.

[5]  M. Guerrero,et al.  MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer , 2012, Cancer.

[6]  E. Kimura,et al.  MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer , 2012, Oncogene.

[7]  F. Yu,et al.  Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. , 2012, The Journal of clinical endocrinology and metabolism.

[8]  A. Fusco,et al.  Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. , 2012, The Journal of clinical endocrinology and metabolism.

[9]  Federica Gemignani,et al.  Role of variations within microRNA-binding sites in cancer. , 2012, Mutagenesis.

[10]  Chunxiang Zhang,et al.  Cell-specific effects of miR-221/222 in vessels: molecular mechanism and therapeutic application. , 2012, Journal of molecular and cellular cardiology.

[11]  D. Frezzetti,et al.  The microRNA-Processing Enzyme Dicer Is Essential for Thyroid Function , 2011, PloS one.

[12]  E. Kebebew,et al.  MiR-886-3p Regulates Cell Proliferation and Migration, and Is Dysregulated in Familial Non-Medullary Thyroid Cancer , 2011, PloS one.

[13]  G. Chiappetta,et al.  miR-191 down-regulation plays a role in thyroid follicular tumors through CDK6 targeting. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  Marina N. Nikiforova,et al.  Molecular genetics and diagnosis of thyroid cancer , 2011, Nature Reviews Endocrinology.

[15]  S. Hüttelmaier,et al.  Pathogenic mechanisms of deregulated microRNA expression in thyroid carcinomas of follicular origin , 2011, Thyroid research.

[16]  A. Fusco,et al.  MiR-1 is a tumor suppressor in thyroid carcinogenesis targeting CCND2, CXCR4, and SDF-1alpha. , 2011, The Journal of clinical endocrinology and metabolism.

[17]  Wei Wang,et al.  Polymorphism of the pre-miR-146a is associated with risk of cervical cancer in a Chinese population. , 2011, Gynecologic oncology.

[18]  Bin Zhou,et al.  Common genetic polymorphisms in pre‐microRNAs and risk of cervical squamous cell carcinoma , 2011, Molecular carcinogenesis.

[19]  A. Gill,et al.  MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer Identifies Predictors of Nodal Metastasis, Prognosis, and Potential Therapeutic Targets , 2011, Clinical Cancer Research.

[20]  R. Paschke,et al.  Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. , 2011, The Journal of clinical endocrinology and metabolism.

[21]  M. Brandi,et al.  MicroRNA Role in Thyroid Cancer Development , 2011, Journal of thyroid research.

[22]  M. Nikiforova,et al.  MicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma , 2011, Annals of Surgical Oncology.

[23]  Roy Phitayakorn,et al.  Follicular adenoma and carcinoma of the thyroid gland. , 2011, The oncologist.

[24]  L. Chin,et al.  Making sense of cancer genomic data. , 2011, Genes & development.

[25]  M. Ceccarelli,et al.  Upregulation of miR-21 by Ras in vivo and its role in tumor growth , 2011, Oncogene.

[26]  Yong Huang,et al.  Biological functions of microRNAs: a review , 2011, Journal of Physiology and Biochemistry.

[27]  H. Dralle,et al.  Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas , 2010, Oncogene.

[28]  Kuender D Yang,et al.  miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation. , 2010, Thyroid : official journal of the American Thyroid Association.

[29]  C. Croce,et al.  Deregulation of microRNA expression in follicular-cell-derived human thyroid carcinomas. , 2010, Endocrine-related cancer.

[30]  K. Schmid,et al.  Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours , 2009, British Journal of Cancer.

[31]  Hong Wang,et al.  miRNA expression in a human papillary thyroid carcinoma cell line varies with invasiveness. , 2010, Endocrine journal.

[32]  M. Nikiforova,et al.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. , 2009, Surgery.

[33]  J. Ricarte-Filho,et al.  Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer. , 2009, Translational oncology.

[34]  M. Guerrero,et al.  Diagnostic markers and prognostic factors in thyroid cancer. , 2009, Future oncology.

[35]  D. Guidolin,et al.  miR-17 family of microRNAs controls FGF10-mediated embryonic lung epithelial branching morphogenesis through MAPK14 and STAT3 regulation of E-Cadherin distribution. , 2009, Developmental biology.

[36]  Xiuping Liu,et al.  Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells , 2009, Autophagy.

[37]  M. Menon,et al.  Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications , 2009, Journal of Clinical Pathology.

[38]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[39]  K. Schmid,et al.  Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[40]  M. Nikiforova,et al.  MicroRNA Expression Profiles in Thyroid Tumors , 2009, Endocrine pathology.

[41]  K. Zatloukal,et al.  miR‐29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis , 2009, EMBO reports.

[42]  Bo Liu,et al.  miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. , 2009, Journal of hepatology.

[43]  P. Northcott,et al.  MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma , 2009, PloS one.

[44]  Kedar S Vaidya,et al.  Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. , 2009, Cancer research.

[45]  B. Shastry.  SNPs: impact on gene function and phenotype. , 2009, Methods in molecular biology.

[46]  A. Komar.  Single Nucleotide Polymorphisms , 2009, Methods in Molecular Biology™.

[47]  N. Mitsiades,et al.  Molecular pathology of thyroid cancer: diagnostic and clinical implications. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[48]  H. Gharib,et al.  Epidemiology of thyroid nodules. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[49]  Cameron P Bracken,et al.  MicroRNAs as regulators of epithelial-mesenchymal transition , 2008, Cell cycle.

[50]  A. Pinchera,et al.  BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[51]  S. Schokrpur,et al.  Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells , 2008, Oncogene.

[52]  M. Korpal,et al.  The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis , 2008, RNA biology.

[53]  T. Fahey,et al.  MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma , 2008, Modern Pathology.

[54]  T. Yau,et al.  Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients With Localized Disease Treated by Combination of Surgery and Radiotherapy , 2008, Annals of Surgical Oncology.

[55]  M. Biffoni,et al.  A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis , 2008, Nature Cell Biology.

[56]  C. Croce,et al.  MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer , 2008, Oncogene.

[57]  H. Namba,et al.  Oncogenic role of miR‐17‐92 cluster in anaplastic thyroid cancer cells , 2008, Cancer science.

[58]  Barbara Jarzab,et al.  Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma , 2008, Proceedings of the National Academy of Sciences.

[59]  G. Botti,et al.  HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. , 2008, European journal of cancer.

[60]  G. Tseng,et al.  MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.

[61]  高倉 修.  Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells , 2008 .

[62]  A. Pinchera,et al.  Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. , 2008, The Journal of clinical endocrinology and metabolism.

[63]  G. Wakabayashi,et al.  Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines , 2008, Cancer science.

[64]  Michael T. McManus,et al.  Behind the scenes of a small RNA gene-silencing pathway. , 2008, Human gene therapy.

[65]  E. Kebebew,et al.  Recent developments in the clinical application of thyroid cancer biomarkers , 2008, Current opinion in oncology.

[66]  Zhen Lin,et al.  Epstein-Barr Virus Latent Membrane Protein 1 Induces Cellular MicroRNA miR-146a, a Modulator of Lymphocyte Signaling Pathways , 2007, Journal of Virology.

[67]  M. Xing,et al.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. , 2007, Endocrine reviews.

[68]  Wolfgang A. Schulz,et al.  Downregulation of several fibulin genes in prostate cancer , 2007, The Prostate.

[69]  C. Croce,et al.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas , 2007, Oncogene.

[70]  C. Hother,et al.  MicroRNAs and cancer , 2007, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[71]  Giovanni Vanni Frajese,et al.  miR-221 and miR-222 Expression Affects the Proliferation Potential of Human Prostate Carcinoma Cell Lines by Targeting p27Kip1* , 2007, Journal of Biological Chemistry.

[72]  Stephen R. Master,et al.  Differential Expression of miRNAs in Papillary Thyroid Carcinoma Compared to Multinodular Goiter Using Formalin Fixed Paraffin Embedded Tissues , 2007, Endocrine pathology.

[73]  D. McMillin,et al.  Targeting BRAFV600E in thyroid carcinoma: therapeutic implications , 2007, Molecular Cancer Therapeutics.

[74]  A. Lewiński,et al.  BRAF mutations in papillary thyroid carcinoma. , 2006, Endocrine regulations.

[75]  C. Eng,et al.  A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[76]  D. Baltimore,et al.  NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[77]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[78]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[79]  S. Asa,et al.  Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.

[80]  C. Croce,et al.  The role of microRNA genes in papillary thyroid carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  C. Croce,et al.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[82]  G. Maira,et al.  Extensive modulation of a set of microRNAs in primary glioblastoma. , 2005, Biochemical and biophysical research communications.

[83]  Lei Zhang,et al.  Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. , 2005, Cancer research.

[84]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[85]  V. Ambros.  The functions of animal microRNAs , 2004, Nature.

[86]  M. Kruhøffer,et al.  Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas , 2004, Oncogene.

[87]  H. Gharib.  Changing trends in thyroid practice: understanding nodular thyroid disease. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[88]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[89]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[90]  Victor Smetacek,et al.  Making sense , 2004, Nature.

[91]  L. Greene,et al.  Fibulins: physiological and disease perspectives , 2003, EMBO reports.

[92]  C. Jasmin,et al.  Tetraspanins and malignancy , 2001, Expert Reviews in Molecular Medicine.

[93]  P. Laurent-Puig,et al.  Human fibulin‐4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues , 2001, FEBS letters.

[94]  H. Röher,et al.  Activin A and activin receptors in thyroid cancer. , 2001, Thyroid : official journal of the American Thyroid Association.

[95]  P. Herrlich,et al.  Recent advances in the genetics of metastasis. , 1994, European journal of cancer.

[96]  K. Hagino-Yamagishi,et al.  [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.

[97]  T. Rephann,et al.  Association , 1973, ACM SIGSPATIAL International Workshop on Advances in Geographic Information Systems.